ADMD - Advanced Medical Isotope Corporation

Other OTC - Other OTC Delayed Price. Currency in USD

Advanced Medical Isotope Corporation

1021 North Kellogg Street
Kennewick, WA 99336
United States

Full Time Employees

Key Executives

Dr. Carlton M. Cadwell D.D.S.Chairman & Sec.N/AN/A72
Dr. Michael K. Korenko Ph.D.CEO, Pres & DirectorN/AN/A71
Mr. Leonard Bruce JolliffChief Financial Officer180kN/A67
Dr. Nigel R. Stevenson Ph.D.Chief Science Officer and Member of Scientific Advisory CommitteeN/AN/AN/A
Dr. Fu-Min Su Ph.D.Chief Radio Chemist and Radiation Safety OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Advanced Medical Isotope Corporation, a radiation oncology focused medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. Its brachytherapy products include yttrium-90 RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. The company serves government and commercial customers in the medical and veterinary sectors. Advanced Medical Isotope Corporation was incorporated in 1994 is headquartered in Kennewick, Washington.

Corporate Governance

Advanced Medical Isotope Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.